Ribonucleotide reductase subunit M2 (RRM2), an enzyme that catalyzes the synthesis of deoxyribonucleotides, is involved in tumor progression in many types of cancer, especially upregulated in sunitinib‐resistant RCC cells.[47] Studies in Saccharomyces cerevisiae indicate that the CSN6 contributes to gemcitabine resistance.[48] Data mining of Cancer Therapeutics Response Portal (CTRP) dataset and CCLE indicated that CSN6 expression level indeed correlates with gemcitabine's IC50 value in PDAC cell lines. Here, RRM2 is linked to neoplasm.